Apyx Medical highlighted another industry recognition for Renuvion as the company continues expanding its minimally invasive body contouring platform.
Key Investor Takeaways
- Apyx Medical (NASDAQ:APYX) said Renuvion received the 2026 NewBeauty Award for “Best Minimally Invasive Skin Tightener” for the second straight year.
- The announcement reinforces Renuvion’s positioning in the minimally invasive body contouring market.
- Renuvion remains the only device FDA-cleared for use following liposuction for aesthetic body contouring procedures.
- The company continues integrating Renuvion with its AYON Body Contouring System to expand physician workflow and treatment capabilities.
- Brand visibility and physician adoption remain important drivers for Apyx’s commercial growth narrative.
Why APYX Stock Is in Focus
Apyx Medical (NASDAQ:APYX) announced that its Renuvion platform won the 2026 NewBeauty Award in the “Best Minimally Invasive Skin Tightener” category for the second consecutive year.
The recognition comes as the company continues positioning Renuvion as a leading technology for minimally invasive body contouring procedures. According to the company, Renuvion is currently the only FDA-cleared device indicated for coagulation of subcutaneous soft tissue following liposuction for aesthetic body contouring.
Apyx also emphasized the combination of Renuvion with its AYON Body Contouring System, which the company says helps physicians improve workflow efficiency and offer more customizable procedures.
“We’re proud to be recognized by NewBeauty again,” said Charlie Goodwin, President and CEO of Apyx Medical. “This award reflects the real impact Renuvion has for both physicians and their patients. Together with our provider community, we’re helping more people achieve visible, confidence-building results through advanced, minimally invasive procedures. As the #1 trusted body contouring technology by surgeons², Renuvion continues to expand what’s possible, equipping physicians to deliver consistent outcomes patients can see and feel.”
Why This Matters for Investors
While the announcement is not tied to earnings or regulatory developments, it may still matter to investors because physician awareness and brand positioning are important in the competitive aesthetics market.
Industry awards and third-party recognition can support marketing efforts and potentially strengthen adoption among surgeons considering body contouring technologies. For companies like Apyx, commercial traction often depends heavily on physician confidence, procedural outcomes, and differentiation from competing platforms.
The company’s emphasis on Renuvion’s FDA-cleared indication following liposuction may also reinforce its positioning within minimally invasive aesthetic procedures, a segment that continues to attract interest from both providers and patients.
At the same time, investors may remain focused on whether recognition and branding efforts ultimately translate into higher procedure volumes, recurring utilization, and sustained revenue growth.
What to Watch Next
Investors will likely monitor future updates on physician adoption, utilization trends, and commercial expansion tied to the Renuvion and AYON platforms.
Additional focus may center on whether the company can continue expanding its presence in minimally invasive body contouring while maintaining differentiation in the broader surgical aesthetics market.